Breaks Categories: Stock Spotlights

FridayMay 22, 2026 3:28 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. “One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions,”…

Continue Reading

ThursdayMay 21, 2026 12:55 pm

BioMedNewsBreaks — Why SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. “Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments,” a recent article reads. “Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic.…

Continue Reading

TuesdayMay 19, 2026 2:28 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advancing Workplace Safety with AI-Powered Technology

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is introducing a novel system aimed at identifying drug and alcohol impairment, initially focused on the South American mining sector, where remote operations and heavy machinery make safety monitoring critical. An article discussing this reads, “The biotechnology company, which has spent several years conducting research into intoxication detection, has developed a voice-based AI system designed to identify signs of alcohol or drug impairment within seconds, the first of its kind in the world. Instead of relying on traditional biological testing methods…

Continue Reading

TuesdayMay 19, 2026 1:58 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments,” reads a recent article. “At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable…

Continue Reading

FridayMay 15, 2026 12:02 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet demands as cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide. “Cardio Diagnostics is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized cardiovascular insights from a simple blood sample, positioning itself at the intersection of precision medicine and preventive care,” reads a recent article. “Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. The…

Continue Reading

WednesdayMay 06, 2026 1:22 pm

BioMedNewsBreaks — AI Meets Multi-Omics: Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Earlier, More Precise Cardiac Insights

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. “Cardio Diagnostics Holdings is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (‘AI’) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions,” the publication reads. “Despite advances in medicine, a key challenge in managing cardiovascular disease is that it often develops silently over…

Continue Reading

ThursdayApr 30, 2026 1:59 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Precision Cardiology with Multi-Omic AI Platform

Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. The company is “developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample,” reads a recent article. “At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional…

Continue Reading

WednesdayApr 29, 2026 2:15 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Leveraging Vertical Integration to Target Precision Medicine Market

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to build vertical integration across telemedicine, pharmaceuticals, and clinical services. “At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific patient needs. This segment aims to tackle the growing gap in traditional pharmaceutical manufacturing… Through operating licensed compounding facilities, the company is strategically positioned to serve a niche but quickly evolving market driven by demand for precision treatment and specialized formulations,” reads the publication. “In addition to this, the company’s telemedicine infrastructure operates as a front-end patient acquisition…

Continue Reading

FridayApr 24, 2026 2:57 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. “By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.” To view the full article, visit https://ibn.fm/EE6ya About LIXTE Biotechnology Holdings Inc. LIXTE…

Continue Reading

FridayApr 24, 2026 2:24 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Toward Commercial Deployment of AI Solution

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent article that discussed its move toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The publication reads, “The biotechnology company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from technology development to field implementation in large enterprise environments… Leyton brings experience in national drug policy and…

Continue Reading